论文部分内容阅读
目的观察CTV化疗方案治疗视网膜母细胞瘤的相关不良反应及其防治措施。方法选取2008年1月至2008年12月临床确诊为视网膜母细胞瘤并化疗的患儿,共154例。采用CTV化疗方案(卡铂28 mg/kg、替尼泊苷8 mg/kg、长春新碱0.05 mg/kg),观察患儿化疗时及化疗后的不良反应。结果未摘除眼球的眼内期患儿化疗后肿瘤明显缩小。化疗时及化疗后无任何不良反应者3例,占1.9%;有不良反应按WHO化疗不良反应分级为Ⅰ度者48例,占31.2%;Ⅱ度64例,占41.6%;Ⅲ度28例,占18.2%,Ⅳ度11例,占7.1%。不良反应主要为血液系统和消化系统症状、脱发,少数病例出现发热、过敏和周围神经症状;除脱发外,其余不良反应均恢复。结论 CTV化疗方案治疗视网膜母细胞瘤安全、有效。
Objective To observe the adverse effects of CTV chemotherapy in the treatment of retinoblastoma and its prevention and treatment. Methods From January 2008 to December 2008 clinically diagnosed as retinoblastoma and chemotherapy in children, a total of 154 cases. CTV chemotherapy (carboplatin 28 mg / kg, teniposide 8 mg / kg, vincristine 0.05 mg / kg) was used to observe the adverse reactions of chemotherapy and chemotherapy. The results did not remove the eye of children with intraocular tumor chemotherapy significantly reduced. Chemotherapy and chemotherapy without any adverse reactions in 3 cases, accounting for 1.9%; adverse reactions according to WHO chemotherapy adverse reactions grade Ⅰ degree in 48 cases, accounting for 31.2%; Ⅱ degree 64 cases, accounting for 41.6%; Ⅲ degree 28 cases , Accounting for 18.2%, Ⅳ degree in 11 cases, accounting for 7.1%. Adverse reactions were mainly blood system and digestive system symptoms, hair loss, fever, allergies and peripheral neurological symptoms in a few cases. All the adverse reactions recovered except hair loss. Conclusion CTV chemotherapy for the treatment of retinoblastoma safe and effective.